Biocon Ltd
NSE:BIOCON

Watchlist Manager
Biocon Ltd Logo
Biocon Ltd
NSE:BIOCON
Watchlist
Price: 329.55 INR -1.91% Market Closed
Market Cap: 394.7B INR
Have any thoughts about
Biocon Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

35.8
Current
32.9
Median
4
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
35.8
=
Enterprise Value
537.3B INR
/
EBIT
15B INR
All Countries
Close
Market Cap EV/EBIT
IN
Biocon Ltd
NSE:BIOCON
395.7B INR 35.8
FR
Pharnext SCA
OTC:PNEXF
6T USD -216 971.5
US
Abbvie Inc
NYSE:ABBV
311.8B USD 23.4
US
Amgen Inc
NASDAQ:AMGN
140.7B USD 30.5
US
Gilead Sciences Inc
NASDAQ:GILD
115.7B USD 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.7B USD 21.9
US
Epizyme Inc
F:EPE
94.1B EUR -501.1
AU
CSL Ltd
ASX:CSL
134.4B AUD 24.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78B USD 17
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
36B EUR -79.8
EBIT Growth EV/EBIT to Growth
IN
Biocon Ltd
NSE:BIOCON
Average EV/EBIT: 23.3
35.8
81%
0.4
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 971.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.4
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.5
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.9
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -501.1 N/A N/A
AU
CSL Ltd
ASX:CSL
24.6
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.8 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
31.7
2-Years Forward
EV/EBIT
20.8
3-Years Forward
EV/EBIT
16.6

See Also

Discover More